Company intelligence / Profile preview

VISEN Pharmaceuticals

Shanghai, Shanghai, Chinavisenpharma.com ↗

Ownership: Public · 2561
Development stage: Phase 3

Overview

VISEN has three main products in its pipeline. Palopegteriparatide (TransCon PTH) is approved in the EU for hypoparathyroidism. Lonapegsomatropin-tcgd is approved in the US for growth hormone deficiency. Navepegritide (TransCon CNP) is in Phase 2/3 trials for achondroplasia.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: PeptidesHormonesRecombinant polypeptidesSynthetic peptides
Industry: Biotech

Drug pipeline

1 asset

inpegsomatropin

Unknown

Partnerships

Shanghai Pharmaceuticals Holding (SPH Group)WuXi BiologicsUnited Family HealthcareMedSciAscendis Pharma A/S

Beyond the preview

Go deeper on VISEN Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VISEN Pharmaceuticals.

Explore the full profile